Racotumomab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) 是一种抗独特型单克隆抗体 (MAb)。Racotumomab 可与含有 Neu-glycolyl (NeuGc) 的神经节苷脂、硫苷脂和肿瘤中表达的其他抗原发生反应。Racotumomab 是一种抗癌剂，可用于肺癌的研究。

Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is an anti-idiotype monoclonal antibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer.

Racotumomab induces a specific humoral and cellular immune response against the NeuGcGM3 ganglioside present in tumor cells, stimulating the cell death.

Racotumomab (50 μg/dose, i.p.) together with Keyhole limpet hemocyanin (KLH) inhibits tumor growth in F3II cell (s.c.) mammary tumor mice model.Racotumomab (50 μg/dose, s.c.) together with Pemetrexed (100 mg/kg) is highly effective against lung nodules in 3LL cell (s.c.) mice xenograft.Racotumomab (50-200 μg/dose, s.c.) shows no significant antitumor effect in 3LL cell (s.c.) mice xenograft.Animal Model:3LL cell (s.c.) mice xenograftDosage:50 μg/dose, together with Pemetrexed (100 mg/kg)Administration:Subcutaneous injection (s.c.)Result:Reduced lung nodules.

——

Others

Other Targets

Others

——

——

946832-34-4

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years